Research & Literature

AA amyloidosis treated with tocilizumab: case series and updated literature review.

Courties A, Grateau G, Philippe P, et al.

Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis 2015; (22(2)):84-92 doi:10.3109/13506129.2014.1002031.

Therapeutic blockade of interleukin-6 by tocilizumab in the management of AA amyloidosis and chronic inflammatory disorders: a case series and review of the literature.

Lane T, Gillmore JD, Wechalekar AD, et al.

Clinical and experimental rheumatology 2015; (33(6 Suppl 94)):S46-53.

Characteristics of AA amyloidosis patients in San Francisco.

Lejmi H, Jen KY, Olson JL, et al.

Nephrology (Carlton, Vic.) 2016; (21(4)):308-13 doi:10.1111/nep.12616.

[Pathological and clinical correlations in renal AA amyloidosis: A Moroccan series of 30 cases].

Bziz A, Rouas L, Lamalmi N, et al.

Nephrologie & therapeutique 2015; (11(7)):543-50.

Efficacy of anti-IL-1 treatment in familial Mediterranean fever: a systematic review of the literature.

van der Hilst JCh, Moutschen M, Messiaen PE, et al.

Biologics : targets & therapy 2016; (10()):75-80 doi:10.2147/BTT.S102954.

Long-term prognosis of AL and AA renal amyloidosis: a Japanese single-center experience.

Ozawa M, Komatsuda A, Ohtani H, et al.

Clinical and experimental nephrology 2017; (21(2)):212-227 doi:10.1007/s10157-016-1271-y.

A multicenter report of biologic agents for the treatment of secondary amyloidosis in Turkish rheumatoid arthritis and ankylosing spondylitis patients.

Pamuk ÖN, Kalyoncu U, Aksu K, et al.

Rheumatology international 2016; (36(7)):945-53 doi:10.1007/s00296-016-3500-9.

Anti-TNFα therapy for chronic inflammatory disease in kidney transplant recipients: Clinical outcomes.

Garrouste C, Anglicheau D, Kamar N, et al.

Medicine 2016; (95(41)):e5108 doi:10.1097/MD.0000000000005108.

Medication-Induced Interstitial Nephritis in the 21st Century.

Nast CC

Advances in chronic kidney disease 2017; (24(2)):72-79 doi:10.1053/j.ackd.2016.11.016.

[AA amyloidosis].

Stojanovic KS, Georgin-Lavialle S, Grateau G

Nephrologie & therapeutique 2017; (13(4)):258-264 doi:10.1016/j.nephro.2017.03.001.

Gastrointestinal Amyloidosis: Review of the Literature.

Rowe K, Pankow J, Nehme F, Salyers W

Cureus 2017; (9(5)):e1228 doi:10.7759/cureus.1228.

Significant association between renal function and area of amyloid deposition in kidney biopsy specimens in both AA amyloidosis associated with rheumatoid arthritis and AL amyloidosis.

Kuroda T, Tanabe N, Hasegawa E, et al.

Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis 2017; (24(2)):123-130 doi:10.1080/13506129.2017.1338565.

Increasing the accuracy of proteomic typing by decellularisation of amyloid tissue biopsies.

Mangione PP, Mazza G, Gilbertson JA, et al.

Journal of proteomics 2017; (165()):113-118 doi:10.1016/j.jprot.2017.06.016.

Serum amyloid A forms stable oligomers that disrupt vesicles at lysosomal pH and contribute to the pathogenesis of reactive amyloidosis.

Jayaraman S, Gantz DL, Haupt C, Gursky O

Proceedings of the National Academy of Sciences of the United States of America 2017; (114(32)):E6507-E6515 doi:10.1073/pnas.1707120114.

Safety and efficacy of empirical interleukin-1 inhibition using anakinra in AA amyloidosis of uncertain aetiology.

Lane T, Wechalekar AD, Gillmore JD, et al.

Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis 2017; (24(3)):189-193 doi:10.1080/13506129.2017.1352503.

Pathology and diagnosis of renal non-AL amyloidosis.

Sethi S, Theis JD

Journal of nephrology 2018; (31(3)):343-350 doi:10.1007/s40620-017-0426-6.

Long-term follow-up of secondary amyloidosis patients treated with tumor necrosis factor inhibitor therapy: A STROBE-compliant observational study.

Esatoglu SN, Hatemi G, Ugurlu S, et al.

Medicine 2017; (96(34)):e7859 doi:10.1097/MD.0000000000007859.

Variation of amino acid sequences of serum amyloid a (SAA) and immunohistochemical analysis of amyloid a (AA) in Japanese domestic cats.

Tei M, Uchida K, Chambers JK, et al.

The Journal of veterinary medical science 2018; (80(1)):164-172 doi:10.1292/jvms.17-0447.

Efficacy and safety of interleukin-1 inhibitors in familial Mediterranean fever patients complicated with amyloidosis.

Varan Ö, Kucuk H, Babaoglu H, et al.

Modern rheumatology 2019; (29(2)):363-366 doi:10.1080/14397595.2018.1457469.

First Nationwide Survey of 199 Patients with Amyloid A Amyloidosis in Japan.

Okuda Y, Yamada T, Ueda M, Ando Y

Internal medicine (Tokyo, Japan) 2018; (57(23)):3351-3355 doi:10.2169/internalmedicine.1099-18.

AA amyloidosis - Benefits and prospects of IL-6 inhibitors.

Okuda Y

Modern rheumatology 2019; (29(2)):268-274 doi:10.1080/14397595.2018.1515145.

Intestinal involvement in amyloidosis is a sequential process.

den Braber-Ymker M, Heijker S, Lammens M, et al.

Neurogastroenterology and motility 2018; (30(12)):e13469 doi:10.1111/nmo.13469.

Secondary, AA, Amyloidosis.

Papa R, Lachmann HJ

Rheumatic diseases clinics of North America 2018; (44(4)):585-603 doi:10.1016/j.rdc.2018.06.004.

Clinical and laboratory profile of renal amyloidosis: A single-center experience.

Engineer DP, Kute VB, Patel HV, Shah PR

Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia 2018; (29(5)):1065-1072 doi:10.4103/1319-2442.243966.

The complementary role of histology and proteomics for diagnosis and typing of systemic amyloidosis.

Rezk T, Gilbertson JA, Mangione PP, et al.

The journal of pathology. Clinical research 2019; (5(3)):145-153 doi:10.1002/cjp2.126.

Lipid membranes accelerate amyloid formation in the mouse model of AA amyloidosis.

Vahdat Shariat Panahi A, Hultman P, Öllinger K, et al.

Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis 2019; (26(1)):34-44 doi:10.1080/13506129.2019.1576606.

The Value of Serum Amyloid A Levels in Familial Mediterranean Fever to Identify Occult Inflammation During Asymptomatic Periods.

Çakan M, Karadağ ŞG, Tanatar A, et al.

Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases 2021; (27(1)):1-4 doi:10.1097/RHU.0000000000001134.

Immunoelectron microscopy and mass spectrometry for classification of amyloid deposits.

Abildgaard N, Rojek AM, Møller HE, et al.

Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis 2020; (27(1)):59-66 doi:10.1080/13506129.2019.1688289.

[Renal amyloidoses in nephrology].

Koumou GCG, Sinomono DTE, Merzouk S, et al.

The Pan African medical journal 2019; (34()):79 doi:10.11604/pamj.2019.34.79.8722.

Cardiac AA amyloidosis in a patient with obstructive hypertrophic cardiomyopathy.

Li B, Ahluwalia M, Narula N, et al.

Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology 2020; (48()):107218 doi:10.1016/j.carpath.2020.107218.

Approach to the Diagnosis of Amyloidosis.

Juneja R, Pati HP

Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion 2020; (36(2)):246-253 doi:10.1007/s12288-019-01208-4.

A histopathological scoring and grading system to predict outcome for patients with AA amyloidosis.

Celtik A, Sen S, Keklik F, et al.

International urology and nephrology 2020; (52(7)):1297-1304 doi:10.1007/s11255-020-02505-y.

Relationship between Modified Body Mass Index and Prognosis of Renal Amyloid a Amyloidosis.

Şahutoğlu T

Sisli Etfal Hastanesi tip bulteni 2018; (52(2)):103-108 doi:10.14744/SEMB.2017.89410.

Diverse patterns of antibody variable gene repertoire disruption in patients with amyloid light chain (AL) amyloidosis.

Chen EC, Rubinstein S, Soto C, et al.

PloS one 2020; (15(7)):e0235713 doi:10.1371/journal.pone.0235713.

Structural Basis for Vital Function and Malfunction of Serum Amyloid A: an Acute-Phase Protein that Wears Hydrophobicity on Its Sleeve.

Gursky O

Current atherosclerosis reports 2020; (22(11)):69 doi:10.1007/s11883-020-00888-y.

Amyloid storm: acute kidney injury and massive proteinuria, rapidly progressing to end-stage kidney disease in AA amyloidosis of familial Mediterranean fever.

Kukuy OL, Beckerman P, Dinour D, et al.

Rheumatology (Oxford, England) 2021; (60(7)):3235-3242 doi:10.1093/rheumatology/keaa772.

Infections and AA amyloidosis: An overview.

Deshayes S, Aouba A, Grateau G, Georgin-Lavialle S

International journal of clinical practice 2021; (75(6)):e13966 doi:10.1111/ijcp.13966.

AA amyloid fibrils from diseased tissue are structurally different from in vitro formed SAA fibrils.

Bansal A, Schmidt M, Rennegarbe M, et al.

Nature communications 2021; (12(1)):1013 doi:10.1038/s41467-021-21129-z.

Blockade of interleukin-6 as a possible therapeutic target for AA amyloidosis.

Almenara Tejederas M, Alonso García F, Aguilera Morales WA, et al.

Nefrologia 2021; doi:10.1016/j.nefro.2021.01.006.

Gastrointestinal AA amyloidosis secondary to chronic pyelonephritis presenting with refractory diarrhea and severe hypoalbuminemia.

Tanaka T, Naito T, Midori Y, et al.

Clinical journal of gastroenterology 2021; (14(6)):1642-1648 doi:10.1007/s12328-021-01508-1.

Amyloidosis and Glomerular Diseases in Familial Mediterranean Fever.

Siligato R, Gembillo G, Calabrese V, et al.

Medicina (Kaunas, Lithuania) 2021; (57(10)) doi:10.3390/medicina57101049.

Dismal Prognosis of Acute Allergic Tubulointerstitial Nephritis in Patients with AA Amyloidosis.

Yildirim T, Gok-Oguz E, Koc NS, et al.

Nephron 2022; (146(2)):172-178 doi:10.1159/000520151.

A multicenter study of the clinical, laboratory characteristics, and potential prognostic factors in patients with amyloid A amyloidosis on hemodialysis.

Bilgic Koylu E, Eren Sadioglu R, Eyupoglu S, et al.

Hemodialysis international. International Symposium on Home Hemodialysis 2022; (26(2)):207-215 doi:10.1111/hdi.12993.

Renal Amyloidosis: Presentation, Diagnosis, and Management.

Gurung R, Li T

The American journal of medicine 2022; (135 Suppl 1()):S38-S43 doi:10.1016/j.amjmed.2022.01.003.

Prognostic value of histopathological scoring and grading in patients with renal AA amyloidosis.

Ozdemir A, Yılmaz M, Ozagari AA, Kocak SY

International urology and nephrology 2022; (54(10)):2591-2597 doi:10.1007/s11255-022-03163-y.

Facing the Challenge of Drug-Induced Acute Interstitial Nephritis.

Sanchez-Alamo B, Cases-Corona C, Fernandez-Juarez G

Nephron 2023; (147(2)):78-90 doi:10.1159/000525561.

Serum Amyloid A Protein-Associated Kidney Disease: Presentation, Diagnosis, and Management.

Thorne J, Clark D, Geldenhuys L, et al.

Kidney medicine 2022; (4(8)):100504 doi:10.1016/j.xkme.2022.100504.

Renal Amyloidosis: Epidemiological, Clinical, and Laboratory Profile in Adults from One Nephrology Center.

Kaaroud H, Harzallah A, Hajji M, et al.

International journal of nephrology 2022; (2022()):8493479 doi:10.1155/2022/8493479.

Blockade of interleukin-6 as a possible therapeutic target for AA amyloidosis.

Almenara-Tejederas M, Alonso-García F, Aguillera-Morales WA, et al.

Nefrologia 2022; (42(1)):28-32 doi:10.1016/j.nefroe.2022.02.003.

Renal amyloidosis: a new time for a complete diagnosis.

Feitosa VA, Neves PDMM, Jorge LB, et al.

Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica 2022; (55()):e12284 doi:10.1590/1414-431X2022e12284.

The relation between C-reactive protein and serum amyloid A in patients with autoinflammatory diseases.

Legger GE, Dermer CWE, Brunger AF, et al.

Pediatric rheumatology online journal 2022; (20(1)):106 doi:10.1186/s12969-022-00757-9.

French practical guidelines for the diagnosis and management of AA amyloidosis.

Georgin-Lavialle S, Savey L, Buob D, et al.

La Revue de medecine interne 2023; (44(2)):62-71 doi:10.1016/j.revmed.2022.12.004.

Characteristics and course of patients with AA amyloidosis: single centre experience with 174 patients from Turkey.

Bektas M, Koca N, Oguz E, et al.

Rheumatology (Oxford, England) 2024; (63(2)):319-328 doi:10.1093/rheumatology/kead465.

Kidney Transplantation in Patients With AA Amyloidosis: Outcomes in a French Multicenter Cohort.

Schwarz C, Georgin-Lavialle S, Lombardi Y, et al.

American journal of kidney diseases : the official journal of the National Kidney Foundation 2024; (83(3)):329-339 doi:10.1053/j.ajkd.2023.07.020.

Tocilizumab (anti-IL-6) treatment for AA renal amyloidosis in a patient with advanced chronic kidney disease, a case report.

Seneschall C, Law S, Roufosse C, et al.

Journal of nephrology 2024; (37(4)):1147-1152 doi:10.1007/s40620-023-01845-z.

AA amyloidosis With Ig-Dominant Staining and Diagnostically Unusual Features.

Andeen NK, DiFranza L, Kung VL, et al.

Kidney international reports 2024; (9(1)):162-170 doi:10.1016/j.ekir.2023.10.005.

AA Amyloidosis: A Contemporary View.

Mirioglu S, Uludag O, Hurdogan O, et al.

Current rheumatology reports 2024; (26(7)):248-259 doi:10.1007/s11926-024-01147-8.

AA amyloidosis in vertebrates: epidemiology, pathology and molecular aspects.

Moccia V, Tucciarone CM, Garutti S, et al.

Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis 2025; (32(1)):3-13 doi:10.1080/13506129.2024.2417219.

Renal outcomes and survival in amyloidosis associated with familial Mediterranean fever: A longitudinal study.

Ozeri DJ, Bar D, Somech Safran B, et al.

Seminars in arthritis and rheumatism 2025; (71()):152642 doi:10.1016/j.semarthrit.2025.152642.

Serum Amyloid A Binding to Glycosaminoglycans is Synergistic with Amyloid Formation: Therapeutic Targeting in the Inflammation-linked Amyloidosis.

Jayaraman S, Urdaneta A, Fandrich M, Gursky O

Journal of molecular biology 2025; (437(8)):169007 doi:10.1016/j.jmb.2025.169007.

The evolving spectrum of kidney amyloidosis: advances in diagnosis, typing and treatment.

Allinovi M, Trivioli G, Gaudio C, et al.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2025; (40(10)):1826-1837 doi:10.1093/ndt/gfaf042.

Use of Biologic Therapy in AA Amyloidosis Patients Undergoing Dialysis-A Systematic Literature Review.

Torun ES, Kadıoğlu G

Hemodialysis international. International Symposium on Home Hemodialysis 2025; (29(4)):450-462 doi:10.1111/hdi.13238.

Efficacy and safety of treatments in familial Mediterranean fever and its complications: a systematic review informing the EULAR/PReS recommendations for familial Mediterranean fever.

Sag E, Otón T, Carmona L, Ozen S

Annals of the rheumatic diseases 2025; (84(11)):1909-1927 doi:10.1016/j.ard.2025.05.020.

Comparative Histopathological Characteristics of Duodenal Involvement in Different Types of Amyloidosis.

Tebenkova A, Gioeva Z, Shakhpazyan N, et al.

Biomedicines 2025; (13(9)) doi:10.3390/biomedicines13092196.

From ulcerative colitis to amyloid storm: a case-based review.

Özkurt S, Cansu DÜ, Yildirim U, et al.

Rheumatology international 2025; (45(11)):263 doi:10.1007/s00296-025-06015-x.

Epigallocatechin-3-Gallate: A potential amyloid Fibril Disaggregator of Serum amyloid A1.

Horgan NG, Djurovic-Topalovic A, Ademoye TA, et al.

Biochemistry and biophysics reports 2025; (44()):102365 doi:10.1016/j.bbrep.2025.102365.

Renal AA amyloidosis associated with inflammatory bowel disease.

Zran N, Chargui S, Azzabi A, et al.

BMC nephrology 2026; (27(1)).

AA amyloidosis with multiorgan involvement secondary to severe hidradenitis suppurativa: A case report.

Armendariz Gayraud J, Albertí Vich F, Torralba Cloquell I, et al.

Medicine 2026; (105(33)):e50113 doi:10.1097/MD.0000000000050113.